March 6 (Reuters) - Lonza will sell its capsules and health ingredients business to private equity firm Lone Star Funds for an enterprise value of 2.3 billion Swiss francs ($3.0 billion), the Swiss
Lonza Sells Capsules and Health Ingredients Arm to Lone Star for $3 Billion
Lonza's Strategic Divestment and Transaction Details
March 6 (Reuters) - Lonza will sell its capsules and health ingredients business to private equity firm Lone Star Funds for an enterprise value of 2.3 billion Swiss francs ($3.0 billion), the Swiss contract drug manufacturer said on Friday.
Background and Rationale
The company has been seeking to exit the business since December 2024, with an aim to focus solely on its core contract drug manufacturing offering.
Key Transaction Details
Financial Terms
- Lonza will receive upfront proceeds of 1.7 billion Swiss francs and retain a 40% stake in the business
- Total undiscounted proceeds are expected to be at or above 3 billion Swiss francs
Timeline and Closing
- The transaction is expected to close in the second half of 2026
Exchange Rate Information
($1 = 0.7777 Swiss francs)
Reporting Credits
(Reporting by Bartosz Dabrowski in Gdansk; Editing by Kristen Donovan)
